Plasma cell leukemia (PCL) is defined as an aggressive plasma cell neoplasm characterized by neoplastic plasma cells in the peripheral blood, with a circulating clonal plasma cell count exceeding 2x10^9/L or 20% of the leukocyte differential count. The packet certifies no associated genes, inheritance pattern, onset category, or prevalence estimate, so these are not described here.

No phenotype annotations or clinical description are certified in this packet. The definition's reference to circulating neoplastic plasma cells in the peripheral blood is the only disease characterization supplied.

The genetic basis, molecular mechanism, and inheritance of this condition are not certified in this packet. No genes are listed, and causes are not described here.

Diagnostic methods and newborn screening information are not certified in this packet.

Treatment coverage is not certified in this packet, and no foundational therapies or approved treatment records are present for this condition. General oncology framing describes treatment planning as depending on disease characteristics and overall health, with care typically involving a multidisciplinary oncology team and goals that may be disease control, symptom management, or curative intent depending on the situation.

Natural history and prognosis are not certified in this packet. The definition characterizes the neoplasm as aggressive, and no survival or outcome figures are supplied.

Certified active trial records are present for plasma cell leukemia and are numerous. Examples in the packet include NCT07605416, titled Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (Phase 2, recruiting, sponsor National Cancer Institute); NCT07652905, a Phase 2 study in newly diagnosed primary plasma cell leukemia (recruiting, Institute of Hematology & Blood Diseases Hospital, China); and NCT05283993, a cohort study of plasma cell disorders (recruiting, Peking University First Hospital). The record set also includes studies of related hematologic conditions such as multiple myeloma. Record titles do not establish what an intervention does. Active clinical trials for this condition are listed on ClinicalTrials.gov.